Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by wyndeweston Jun 15, 2017 7:42pm
212 Views
Post# 26368845

RE:RE:RE:RE:RE:Someone knew - there must have been a leak!

RE:RE:RE:RE:RE:Someone knew - there must have been a leak!Nikma97, that's pretty much how I see it as well. PLI knows the next step on the part of the FDA is acceptance of  the answered questions, issuing prority review staus and maybe a Pediatric voucher.  Also just to say, It was soooo disappointing that Pierre chose to raise additional funds by diluting the stock further but after thinking about it, perhaps his plan and timing is correct. PLI is now in a position to"'move full steam ahead" and they can do so without a new partner whose interests are almost certainly to be "what's in it for them".  I don't appreciate that P. Lauren has indicated a partnership is coming then does the opposite but in some ways I find it understandable that he wants to do this on his own. And I do think in the end the shareholders will be the beneficiaries of this strategy.
Bullboard Posts